IP Library Granted Patent US 12668623
Granted Patent B2
US 12668623 · App. 18/691,316 · Granted Jun 30, 2026

Anti-periostin humanized monoclonal antibody, and preparation method therefor and use thereof

Inventors: Xuejiao Li (Liaoning, CN); Wei He (Liaoning, CN); Shuo Zhang (Liaoning, CN); Hang Zhao (Liaoning, CN); Ling Feng (Liaoning, CN); Hui Liu (Liaoning, CN); Hongli Zhao (Liaoning, CN); Xiangdong He (Liaoning, CN)
Assignee: Shenyang Eye Industry Technology Institute Ltd.
C07K16/18G01N33/577A61K2039/505C07K2317/24C07K2317/73
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12668623
App. No.
18/691,316
Granted
Jun 30, 2026
Kind
B2
Abstract

Provided in the present application are an anti-periostin humanized monoclonal antibody, and a preparation method therefor and the use thereof. The anti-periostin humanized monoclonal antibody has a relatively high expression level, and also has a better binding specificity and affinity to an antigen.

Claims (12)

1 . A humanized anti-periostin monoclonal antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 2.

2 . The humanized anti-periostin monoclonal antibody according to claim 1 , which comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region is a heavy chain constant region of human IgG1, and the light chain constant region is a light chain constant region of kappa chain.

3 . The humanized anti-periostin monoclonal antibody according to claim 1 , which comprises a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain is set forth in SEQ ID NO: 3, and the amino acid sequence of the light chain is set forth in SEQ ID NO: 4.

4 . A nucleic acid encoding the humanized anti-periostin monoclonal antibody according to claim 1 .

5 . The nucleic acid according to claim 4 , wherein the sequence of the nucleic acid encoding the heavy chain of the humanized anti-periostin monoclonal antibody is SEQ ID NO: 5, and the sequence of the nucleic acid encoding the light chain of the humanized anti-periostin monoclonal antibody is SEQ ID NO: 6.

6 . The nucleic acid according to claim 5 , wherein the sequence of the nucleic acid encoding the heavy chain of the humanized anti-periostin monoclonal antibody is SEQ ID NO: 7, and the sequence of the nucleic acid encoding the light chain of the humanized anti-periostin monoclonal antibody is SEQ ID NO: 8.

7 . An expression vector comprising the nucleic acid according to claim 4 .

8 . The expression vector according to claim 7 , wherein a backbone vector of the expression vector is PATX-GS2.

9 . A host cell transformed or transfected with the expression vector according to claim 8 .

10 . A method for producing the humanized anti-periostin monoclonal antibody according to claim 1 , comprising culturing a host cell transformed or transfected with an expression vector comprising a nucleic acid encoding the humanized anti-periostin monoclonal antibody and inducing the expression of the humanized anti-periostin monoclonal antibody.

11 . A medicament for the treatment of tissue fibrosis and/or a malignant tumor, comprising the humanized anti-periostin monoclonal antibody according to claim 1 .

12 . A kit for diagnosing tissue fibrosis and/or a malignant tumor, comprising the humanized anti-periostin monoclonal antibody according to claim 1 .